Results 101 to 110 of about 1,018 (177)

Structural variations at P1, P2 and P3 for dipeptidyl nitrile cruzain inhibitors.

, 2015
Structural variations at P1, P2 and P3 for dipeptidyl nitrile cruzain inhibitors.
Andrei Leitão (769676), Fabiana Rosini (769679), Leandro A. A. Avelar (769671), Sérgio de Albuquerque (769673), Carlos A. Montanari (449507), Jean F. R. Ribeiro (769678), Cristiana Gonçalez (769674), Erika V. Meñaca Orozco (769677), Peter W. Kenny (769675), William B. Fernandes (449501), James H. McKerrow (113918), Marta E. Saidel (769680), Cristian D. Camilo (769672), Josmar R. Rocha (449500)   +13 more
core   +1 more source

Cruzain [PDF]

Science-Business eXchange, 2008
openaire   +1 more source

Small Molecule Inhibitors of Cruzain for Treatment of Chagas' Disease.

, 2016
Chagas' disease, a neglected tropical disease, affects millions worldwide. This zoonosis occurs as a result of parasitic invasion. The etiological organism, Trypanosoma cruzi (T. cruzi) enters mammalian host cells by triaatomine insects.
Ahmed, Hijab.
core  

Virtual screening models or cruzain inhibitors: development and Eexperimental validation

, 2008
Com o objetivo de buscar e identificar novo(s) inibidor(es) da cruzaína uma cisteíno-protease do Trypanosoma cruzi, o agente etiológico da doença de Chagas foram propostos, validados e, a seguir, aplicados sobre a biblioteca de compostos ZINC (3.294 ...
Malvezzi, Alberto
core  

From rational design to serendipity: Discovery of novel thiosemicarbazones as potent trypanocidal compounds. [PDF]

Eur J Med Chem, 2022
Braga SFP, Santos VC, Vieira RP, Silva EBD, Monti L, Krake SH, Martinez PDG, Dias LC, Caffrey CR, Siqueira-Neto JL, de Oliveira RB, Ferreira RS.   +11 more
europepmc   +1 more source

Lies and Liabilities: Computational Assessment of High-Throughput Screening Hits to Identify Artifact Compounds. [PDF]

J Med Chem, 2023
Alves VM, Yasgar A, Wellnitz J, Rai G, Rath M, Braga RC, Capuzzi SJ, Simeonov A, Muratov EN, Zakharov AV, Tropsha A.   +10 more
europepmc   +1 more source

Improvement in the production of active cruzain for in vitro inhibitors screening assays

, 2019
Chagas disease is a chronic systemic parasitic infection caused by the protozoan parasite Trypanosoma cruzi. A promising target for potential therapeutics against it is the major cysteine protease expressed by T. cruzi, cruzain.
Baldoni, Hector Armando, Carmona Viglianco, Natalia Evelín, Mascotti, María Laura, Giannini, Fernando A.   +3 more
core  

Evaluating Known Zika Virus NS2B-NS3 Protease Inhibitor Scaffolds via In Silico Screening and Biochemical Assays. [PDF]

Pharmaceuticals (Basel), 2023
Santos LH, Rocha REO, Dias DL, Ribeiro BMRM, Serafim MSM, Abrahão JS, Ferreira RS.   +6 more
europepmc   +1 more source

Molecular Modeling Suggests Cruzain Specificity for Peptide Primaquine Prodrugs

, 2010
Chagas` disease, infection caused by the protozoan Trypanosoma cruzi, is an important, social and medical ailment in the Latin America. This disease is endemic in 21 countries, mostly Latin America countries, with more than 300,000 new cases every year ...
CHIN, Chung Man, MENEZES, Carla Maria de Souza, TROSSINI, Gustavo Henrique Goulart, FERREIRA, Elizabeth Igne   +3 more
core  

Synthesis and Biological Evaluation of Tetrahydroisoquinoline Derivatives as Trypanocidal Agents. [PDF]

ACS Omega
de Moura Lopes JP, Marques GVL, Diniz LA, Côrrea Santos V, Resende DM, Murta SMF, Kohlhoff M, Maltarollo VG, Ferreira RS, Oliveira RB.   +9 more
europepmc   +1 more source